Rising global bond yields, including US 10Y yields at multi month highs, are drawing capital toward fixed income and making it harder for many growth stories to hold attention. AI healthcare stocks linked to transformative artificial intelligence look different. Their appeal rests less on cheap money and more on potential real world impact. This article highlights three AI healthcare stocks from our screener that fit that theme.
The three stocks in this article are just a starting sample, and the full screen surfaced 5 more AI healthcare companies with equally compelling narratives that are not covered here. To identify and analyze the ideas that best fit your approach, head straight into the Transformative Artificial intelligence (AI) Healthcare Stocks screener.
Chugai Pharmaceutical (TSE:4519)
Chugai Pharmaceutical is a Japan based drug company focused on oncology and other specialty therapies, with products such as Hemlibra, Actemra and Avastin, and it is now weaving AI into its R&D through a collaboration with Phylo to run an agentic AI platform across its drug discovery workflow. The business currently reports essentially all of its ¥1,342,808 million revenue from pharmaceuticals, while its scale is reflected in a market cap of about ¥11,327,910.9 million, or roughly ¥11.3 trillion. This means the AI initiative sits on top of a large, diversified therapeutics portfolio rather than driving the bulk of current sales.
Investors looking at Chugai Pharmaceutical are getting a large oncology focused business experimenting with AI driven drug discovery instead of a pure play AI story. The Phylo partnership aims to speed up hit finding and candidate selection, which matters for a company that depends heavily on a few blockbuster drugs and faces future patent and pricing pressure. Strong profitability and a sizeable global footprint give it room to fund these AI efforts, but there are real execution questions around data quality, workflow integration and reliance on Roche that you need to weigh. The main point of interest is how quickly this AI platform turns into credible pipeline milestones and not just headlines.
Chugai Pharmaceutical’s AI push is beginning to reshape a mature oncology business, and the key question is how that will affect the pipeline and profit profile. Get the full picture in the 3 key rewards and 1 important warning sign
Build your own AI healthcare shortlist
Chugai Pharmaceutical and the other two AI healthcare stocks in this article all came from a single screener, but the real edge is in creating your own set of filters. Use our flexible Screener to mix metrics like valuation, balance sheet strength, risks and dividends, or jump straight into our curated Investing Ideas for ready made starting points.
eWeLLLtd (TSE:5038)
eWeLL runs a cloud platform for home based medical care in Japan, with its iBow electronic record system and related tools handling everything from clinical notes to insurance claims for visiting nursing stations. The company generates all of its ¥3,781 million revenue from providing services to home visit nursing stations, and its iBow version equipped with an AI home nursing report is a direct link to AI driven documentation and workflow improvements in remote care. eWeLL has a market cap of about ¥31.6 billion, which puts it firmly in small cap territory.
eWeLL provides exposure to AI in healthcare where it is already embedded in daily clinical work, through the iBow AI home nursing report that helps nurses turn visit data into cleaner documentation and care coordination. Revenue is tightly tied to home visit nursing services. This can create a focused growth story if more providers adopt the platform, but it also leaves the company sensitive to policy changes around home care reimbursement. Recent half year results to June 2026 showed higher sales and net income year on year. An important question for investors is how much of that momentum is coming from AI enabled services and whether those services can move from pilots into a broader rollout.
eWeLL’s AI powered home care platform is already in real clinical workflows, yet the market may still be treating it as just another small cap software story. See how the analyst forecasts for eWeLLLtd frames the next phase and the one factor that could flip sentiment overnight.
FINDEX (TSE:3649)
FINDEX is a Japan based healthtech and medical IT company that supplies software for imaging, electronic records, referrals and clinic workflows, while also offering CocktailAI, a generative AI tool that helps automate medical text such as reports and clinical notes, and DigiWorker RPA for hospital process automation. These AI products connect directly to the theme of using AI to cut documentation time and improve accuracy in everyday care, but they sit within a broader portfolio of medical and public sector solutions rather than dominating current sales. FINDEX has a market cap of about ¥20.8 billion, which puts it in the smaller end of the listed healthcare IT space.
FINDEX may appeal to investors who want exposure to AI in healthcare that is already tied to real world hospital workflows instead of being a pure research story. CocktailAI and DigiWorker aim to cut the administrative burden on clinicians by automating repetitive documentation, while the wider suite of imaging, records and referral tools provides multiple points of integration. Recent half year numbers, with revenue of ¥3,145.42 million and lower net income of ¥560.69 million, point to the cost of investing in this push and the execution risk if customers are slow to adopt. The combination of the current earnings profile, an 18.69% forecast earnings growth figure and a board refresh makes the next few reporting periods a useful reference point for anyone tracking how AI healthcare tools affect FINDEX’s business performance.
FINDEX’s AI push and its current earnings profile could be pulling in different directions. See how the analyst forecasts for FINDEX stacks that story against the cost of adoption and one underappreciated turning point that might not be priced in yet.
Seeking Alternatives Beyond AI Healthcare?
Fresh stock ideas move fast. By the time the crowd notices a breakout, the ideal entry can already be gone. Scan these under the radar lists while it matters and act now.
- Spot cash generative companies before momentum really flies by scanning a curated group of 26 high quality undervalued stocks that pair balance sheet strength with disciplined capital allocation.
- Back future infrastructure shifts by reviewing a focused pool of 39 power grid technology and infrastructure stocks that could benefit if grid upgrades and electrification remain in the spotlight.
- Track early compounding potential by filtering a tight set of 55 resilient stocks with low risk scores built around resilient earnings, conservative leverage and lower volatility profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com